HeartBeat.bio AG
PrivateLast Round
VC Round
Nov 2, 2023
Total Funding Raised
$6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
HeartBeat.bio AG is a biotechnology company that develops a high-throughput human organoid and AI-supported drug discovery platform for heart disease.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HeartBeat.bio AG Comparables
Compare HeartBeat.bio AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genome Biologics | 88% | |
| Medera | 84% | |
| Valo Health | 80% |
HeartBeat.bio AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 2, 2023 | ||||
| Seed | May 4, 2021 |
HeartBeat.bio AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vienna Business Agency | Grant |
| Austria Wirtschaftsservice | Grant, Seed, VC Round |
| FFG Austrian Research Promotion Agency | Grant |
| INiTS | Seed |
| Invest AG | VC Round |
| Invest AG | VC Round |
| red-stars.com data | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 5, 2.5x the trailing average.
- Jan 20, 2026
Monthly visitors grew 106% MoM, reaching 7.5K.
Recent news
Latest coverage and updates
- hiresSep 17, 2026
HeartBeat.bio AG hired Stanko Skrtic as Chief Development Officer on Aug 24th '26.
- is_developingSep 9, 2026
HeartBeat.bio AG is developing technologies for cardiovascular drug discovery on Sep 9th '26.
- partners_withSep 8, 2026
HeartBeat.bio AG partnered with Cubase Bio AB on Sep 8th '26.
- is_developingSep 8, 2026
HeartBeat.bio AG is developing scalable approach for analyzing the molecular and cellular mechanisms underlying myocardial fibrosis on Sep 8th '26.
- is_developingAug 12, 2026
HeartBeat.bio AG is developing drug discovery platform based on human heart organoids, known as Cardioids on Aug 12th '26.
HeartBeat.bio AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about HeartBeat.bio AG's valuation, stock price, and market status.
Is HeartBeat.bio AG a public or private company?
HeartBeat.bio AG is a private company.
What is the current stock price of HeartBeat.bio AG?
HeartBeat.bio AG is a private company with no public stock price. No recent secondary market data is available.
How much is HeartBeat.bio AG worth (valuation)?
Valuation information for HeartBeat.bio AG is not publicly available.
Can I buy HeartBeat.bio AG stock?
HeartBeat.bio AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was HeartBeat.bio AG's last funding round?
HeartBeat.bio AG's most recent funding round was VC Round on November 2, 2023.
Who are the main investors in HeartBeat.bio AG?
Key investors in HeartBeat.bio AG include Austria Wirtschaftsservice, Invest AG, red-stars.com data, Tensor Ventures, i&i Prague.
Will HeartBeat.bio AG IPO soon?
No public IPO plans have been announced for HeartBeat.bio AG.
How can I track HeartBeat.bio AG secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor HeartBeat.bio AG's secondary market activity and sign up for updates.